Wave Life Sciences Past Earnings Performance
Past criteria checks 0/6
Wave Life Sciences has been growing earnings at an average annual rate of 15%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 40.2% per year.
Key information
15.0%
Earnings growth rate
40.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 40.2% |
| Return on equity | -95.3% |
| Net Margin | -265.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Nov 15
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Nov 09Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Oct 16There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Sep 25Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Sep 24Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Sep 08We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11Revenue & Expenses Breakdown
How Wave Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 54 | -143 | 57 | 0 |
| 30 Jun 24 | 111 | -73 | 55 | 0 |
| 31 Mar 24 | 113 | -62 | 53 | 0 |
| 31 Dec 23 | 113 | -58 | 51 | 0 |
| 30 Sep 23 | 85 | -85 | 51 | 0 |
| 30 Jun 23 | 37 | -131 | 50 | 0 |
| 31 Mar 23 | 15 | -151 | 50 | 0 |
| 31 Dec 22 | 4 | -162 | 51 | 0 |
| 30 Sep 22 | 4 | -153 | 49 | 0 |
| 30 Jun 22 | 40 | -120 | 50 | 0 |
| 31 Mar 22 | 43 | -118 | 48 | 0 |
| 31 Dec 21 | 41 | -122 | 46 | 0 |
| 30 Sep 21 | 49 | -116 | 44 | 0 |
| 30 Jun 21 | 16 | -143 | 40 | 0 |
| 31 Mar 21 | 16 | -145 | 40 | 0 |
| 31 Dec 20 | 20 | -150 | 43 | 0 |
| 30 Sep 20 | 13 | -178 | 47 | 0 |
| 30 Jun 20 | 13 | -196 | 50 | 0 |
| 31 Mar 20 | 17 | -197 | 51 | 0 |
| 31 Dec 19 | 16 | -194 | 49 | 0 |
| 30 Sep 19 | 17 | -175 | 48 | 0 |
| 30 Jun 19 | 19 | -162 | 45 | 0 |
| 31 Mar 19 | 16 | -156 | 42 | 0 |
| 31 Dec 18 | 14 | -147 | 40 | 0 |
| 30 Sep 18 | 12 | -140 | 34 | 0 |
| 30 Jun 18 | 9 | -127 | 31 | 0 |
| 31 Mar 18 | 5 | -116 | 29 | 0 |
| 31 Dec 17 | 4 | -102 | 27 | 0 |
| 30 Sep 17 | 3 | -90 | 25 | 0 |
| 30 Jun 17 | 3 | -82 | 22 | 0 |
| 31 Mar 17 | 2 | -69 | 19 | 0 |
| 31 Dec 16 | 1 | -56 | 16 | 0 |
| 30 Sep 16 | 1 | -44 | 15 | 0 |
| 30 Jun 16 | 0 | -31 | 13 | 0 |
| 31 Mar 16 | 0 | -24 | 12 | 0 |
| 31 Dec 15 | 0 | -19 | 10 | 0 |
| 30 Sep 15 | 0 | -14 | 8 | 0 |
| 30 Jun 15 | 0 | -10 | 6 | 0 |
| 31 Mar 15 | 0 | -8 | 4 | 0 |
| 31 Dec 14 | 0 | -5 | 3 | 0 |
Quality Earnings: WVE is currently unprofitable.
Growing Profit Margin: WVE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WVE is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare WVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: WVE has a negative Return on Equity (-95.32%), as it is currently unprofitable.